반응식
[N:1]1[C:10]2[C:5](=[CH:6][CH:7]=[CH:8][C:9]=2[NH:11][S:12]([C:15]2[C:20](N)=[CH:19][CH:18]=[CH:17][N:16]=2)(=[O:14])=[O:13])[CH:4]=[CH:3][CH:2]=1.N(OC(C)(C)C)=O.CC(O)=O>C1COCC1>[N:16]1[C:15]2[S:12](=[O:14])(=[O:13])[NH:11][C:9]3[C:8](=[CH:7][CH:6]=[C:5]4[C:10]=3[N:1]=[CH:2][CH:3]=[CH:4]4)[C:20]=2[CH:19]=[CH:18][CH:17]=1참가 물질
5
실험 절차
In a similar fashion using route 16 general procedure 61, using 3-amino-pyridine-2-sulfonic acid quinolin-8-ylamide (Intermediate 303) (180 mg, 0.6 mmol), t-butyl nitrite (0.11 ml, 0.9 mmol), AcOH (1.8 ml) and THF(1.8 ml) gave the title compound (12 mg, 7%) after purification with prep HPLC (neutral conditions).
출처 및 근거
- ORD 기록
- ord-8af1baa5bee5406a897ccc1e59dbee1f
- 출처 데이터셋
- uspto-grants-2015_08
- 특허 번호
- US09102688B2
연결된 노트
불러오는 중…